Effect of Meal and Antisecretory Agents on the Pharmacokinetics of Danoprevir/Ritonavir in Healthy Volunteers Publication Effect of Meal and Antisecretory Agents on the Pharmacokinetics of Danoprevir/Ritonavir in Healthy Volunteers webdev2013 年 10 月 10 日
Influence of Chronic Hepatitis C Infection on Cytochrome P450 3A4 Activity Using Midazolam as an In Vivo Probe Substrate Publication Influence of Chronic Hepatitis C Infection on Cytochrome P450 3A4 Activity Using Midazolam as an In Vivo Probe Substrate webdev2013 年 10 月 1 日
Pharmacokinetics of a Three-way Drug Interaction Between Danoprevir, Ritonavir, and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin Publication Pharmacokinetics of a Three-way Drug Interaction Between Danoprevir, Ritonavir, and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin webdev2013 年 9 月 1 日
Pharmacokinetic-pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies Publication Pharmacokinetic-pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies webdev2013 年 8 月 1 日
A Randomised Study of the Effect of Danoprevir/Ritonavir or Ritonavir on Substrates of Cytochrome P450 (CYP) 3A and 2C9 in Chronic Hepatitis C Patients Using a Drug Cocktail Publication A Randomised Study of the Effect of Danoprevir/Ritonavir or Ritonavir on Substrates of Cytochrome P450 (CYP) 3A and 2C9 in Chronic Hepatitis C Patients Using a Drug Cocktail webdev2013 年 7 月 20 日
Pharmacokinetic and Pharmacodynamic Modeling to Determine the Human Dose of ST-246(R) to Protect Against Smallpox Publication Pharmacokinetic and Pharmacodynamic Modeling to Determine the Human Dose of ST-246(R) to Protect Against Smallpox Although smallpox has been eradicated, the United States government considers it a "material threat" and…webdev2013 年 3 月 1 日
Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro-In Vivo Extrapolation Model Publication Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro-In Vivo Extrapolation Model The pharmacokinetics (PK) of efavirenz (EFV) is characterized by marked inter-patient variability that correlates with…webdev2012 年 10 月 1 日
Pharmacokinetics and Pharmacodynamics of TBR-652, a Novel CCR5 Antagonist, in HIV-1-Infected, Antiretroviral Treatment-experienced and CCR5 Antagonist-naive Patients Publication Pharmacokinetics and Pharmacodynamics of TBR-652, a Novel CCR5 Antagonist, in HIV-1-Infected, Antiretroviral Treatment-experienced and CCR5 Antagonist-naive Patients TBR-652 is a novel CCR5 antagonist with potent in vitro anti-HIV activity. The objective of…webdev2011 年 4 月 12 日
Combining Drug-disease and Economic Modeling to Inform Drug Development Decisions Publication Combining Drug-disease and Economic Modeling to Inform Drug Development Decisions Drug-disease models and clinical trial simulations are increasingly being used to support trial design and…webdev2001 年 11 月 1 日